Across healthcare investing and corporate strategy, Philip H. Luccock has led deal sourcing, due diligence and portfolio oversight for growth-stage companies. He combines operational experience in medical technology with capital allocation skills, structuring minority and control transactions, and guiding exit planning for strategic acquirers and financings. Prior roles include leadership in corporate development and investment teams, and his background includes business education and cross-border transaction experience. Market participants consider him a practical operator-investor who bridges clinical product development and investor return objectives.
Across healthcare investing and corporate strategy, Philip H. Luccock has led deal sourcing, due diligence and portfolio oversight for growth-stage companies. He combines operational experience in medical technology with capital allocation skills, structuring minority and control transactions, and guiding exit planning for strategic acquirers and financings. Prior roles include leadership in corporate development and investment teams, and his background includes business education and cross-border transaction experience. Market participants consider him a practical operator-investor who bridges clinical product development and investor return objectives.
Bridges clinical insight and financial discipline to source and scale growth-stage healthcare technology opportunities. Prefers minority and structured control investments that align operational support with clear exit pathways for strategic acquirers or financings. Emphasizes rigorous clinical and regulatory due diligence, capital-efficient product development milestones, and staged financings tied to technical and commercial inflection points. Time horizon is growth-stage with a three- to seven-year exit orientation; risk is managed through active portfolio oversight, governance terms, and commercialization-focused value-creation plans.
Bridges clinical insight and financial discipline to source and scale growth-stage healthcare technology opportunities. Prefers minority and structured control investments that align operational support with clear exit pathways for strategic acquirers or financings. Emphasizes rigorous clinical and regulatory due diligence, capital-efficient product development milestones, and staged financings tied to technical and commercial inflection points. Time horizon is growth-stage with a three- to seven-year exit orientation; risk is managed through active portfolio oversight, governance terms, and commercialization-focused value-creation plans.
| Trades 529 | Longs Won 225/529 42% | Profit Factor 1.91 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $417,711.3 |
| Average Win $88,840.14 | Best Trade (Jun 30) $8.61M | Sharpe Ratio -9.55 |
| Average Loss -$34,351.13 | Worst Trade (Mar 31) -$1.86M | Z-Score -4.55 (100%) |
| Commissions $0 | Avg. Trade Length 7m 1d | Expectancy $18,045.91 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | 0.01% | 0.1% | 0.59% | 2% | 5.18% | 11.29% | 21.81% | 38.57% | 63.77% |
| Consecutive Losing Trades | 607 | 546 | 486 | 425 | 364 | 304 | 243 | 182 | 121 | 61 |